In this latest episode of the "MHE Talks: Improving Patient Access" series, Senior Editor of MHE, Peter Wehrwein, speaks with Harvey Kaufman, M.D., FCAP, MBA, senior medical director of medical informatics at Quest Diagnostics. The two discussed a recent Quest Diagnostics Health Trends report examining healthcare disparities.
Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.
Patients facing higher out-of-pocket costs predicted procedures would hurt more than procedures with no copay, according to the results of a recent Carnegie Mellon study.